“This is the beginning of a meaningful long-term partnership dedicated to bringing the unique benefits of GMP-certified medical cannabis to patients in Europe,”
Keith Strachan, President and Interim Chief Executive Officer, MediPharm Labs: “Based on our first deliveries under this portfolio agreement, we are ramping up new products that German patients suffering from chronic pain can count on to meet their individual personalized therapeutic needs.”
The first shipments of dry flower were curated by MediPharm Labs from its network of GMP-certified cultivators.
Manufacturing of extract products is taking place at MediPharm Labs Australia, a GMP-certified and fully licensed production facility.
Original release. www.globenewswire.com/news-release/2021/04/01/2203164/0/en/European-Pharmaceutical-Company-STADA-and-MediPharm-Labs-Begin-First-Sales-in-Germany-Under-Exclusive-Agreement.html